Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Research

• Publication date

  2000-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 10910071
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Il-4r expression in AIDS-KS cells and response to rhIL-4 and IL-4 toxin (DAB389-IL-4)

  2004cited by this paper
• Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2.

  1999cited by this paper
• Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy.

  1998cited by this paper
• Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.

  1998cited by this paper
• Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells.

  1998cited by this paper
• IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.

  1998cited by this paper
• Consensus symposium on combined antiviral therapy; overview of interferon and IL-2 combinations for the treatment of HIV infection.

  1996cited by this paper
• Identification of a novel receptor/signal transduction pathway for IL‐15/T in mast cells

  1996cited by this paper
• The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-I-associated disorders.

  1996cited by this paper
• IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels.

  1996cited by this paper
• Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model.

  1996cited by this paper
• IL-15 administration following syngeneic bone marrow transplantation prolongs survival of lymphoma bearing mice.

  1996cited by this paper
• Identification and cloning of a nobel IL - 15 binding protein that is strucurally related to the αchain of the IL - 2 receptor.

  1995cited by this paper
• Growth factors, cytokines and soluble forms of receptor molecules in cancer patients.

  1995cited by this paper
• G-CSF in the biology and treatment of acute myeloid leukemias.

  1995cited by this paper
• Identification and cloning of a novel IL‐15 binding protein that is structurally related to the alpha chain of the IL‐2 receptor.

  1995cited by this paper
• Interleukin-2: its rationale and role in the treatment of patients with cancer.

  1995cited by this paper
• Interleukin-6: biological features and clinical implications.

  1994cited by this paper
• Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.

  1994cited by this paper
• Recombinant single-chain immunotoxins against T and B cell leukemias.

  1994cited by this paper
• Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity.

  1994cited by this paper
• The Clinical Experience with Interleukin-2 in Cancer Therapy

  1994cited by this paper
• The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results.

  1994cited by this paper
• The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

  1994influential reference
• The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results.

  1994cited by this paper
• A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer

  1993cited by this paper
• Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.

  1993cited by this paper
• Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.

  1992cited by this paper
• A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies.

  1992cited by this paper
• Current protocols in immunology

  1991cited by this paper
• Interactions between cytokines and α2-macroglobulin

  1990cited by this paper
• Interactions between cytokines and alpha 2-macroglobulin.

  1990cited by this paper
• Inactivation of human interleukin-2 (IL-2) by alpha 2-macroglobulin-trypsin complexes.

  1986cited by this paper
• Properties of human interleukin-2 receptors expressed on non-lymphoid cells by cDNA transfection.

  1984cited by this paper
• The fate of interleukin-2 after in vivo administration.

  1983cited by this paper

• A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells

  2022cites this paper
• Current overview of the role of immunotherapy in onco‑urology

  2022cites this paper
• Interleukins in the treatment of melanoma

  2022cites this paper
• Tyrosine kinase inhibition alters intratumoral CD8+ T-cell subtype composition and activity.

  2022cites this paper
• Next Generation Natural Killer Cells for Cancer Immunotherapy

  2022cites this paper
• Multi-Level Computational Modeling of Anti-Cancer Dendritic Cell Vaccination Utilized to Select Molecular Targets for Therapy Optimization

  2022cites this paper
• An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity

  2021cites this paper
• Cytokines in the Treatment of Melanoma

  2021cites this paper
• Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma

  2020cites this paper
• Biodistribution and Anticancer Characteristics of Les-3833, A Novel 4-thiazolidinone-Based Lead Compound

  2020cites this paper
• Interleukin-15 after Near-Infrared Photoimmunotherapy (NIR-PIT) Enhances T Cell Response against Syngeneic Mouse Tumors

  2020cites this paper
• Cytokine Therapeutics in Cancer Immunotherapy: Design and Development

  2019influential citation
• Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy.

  2019cites this paper
• An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck

  2019cites this paper
• Novel Immunotherapies and Novel Combinations of Immunotherapy

  2019cites this paper
• The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex

  2018cites this paper
• IL-2 and Beyond in Cancer Immunotherapy

  2018cites this paper
• Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy

  2018cites this paper
• a novel multifunctional anti-cea-il15 molecule displays potent antitumor activities

  2018cites this paper
• A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities

  2018cites this paper
• An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression

  2018cites this paper
• The role of IFNAR and MyD 88 signaling in induction of IL-15 expression in vivo 1

  2017cites this paper
• IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

  2016cites this paper
• Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models

  2015cites this paper
• A targeted IL-15 fusion protein with potent anti-tumor activity

  2015cites this paper
• Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells Producing IL15 Eradicate Established Pancreatic Tumor in Syngeneic Mice

  2014cites this paper
• Combined Stimulation of IL-2 and 4-1BB Receptors Augments the Antitumor Activity of E7 DNA Vaccines by Increasing Ag-Specific CTL Responses

  2013cites this paper
• Design and characterization of a protein superagonist of IL‐15 fused with IL‐15Rα and a high‐affinity T cell receptor

  2012cites this paper
• This information is current as Expression In Vivo and MyD 88 Signaling in Induction of IL-15 Receptor α Cutting Edge : The Role of IFN-Plumlee

  2012cites this paper
• Cutting Edge: The Role of IFN-α Receptor and MyD88 Signaling in Induction of IL-15 Expression In Vivo

  2012cites this paper
• Interleukin-15 enhances T-cell responses by stimulation with dendritic cells

  2011cites this paper
• Interleukin-15 Receptor Is Essential to Facilitate GABA Transmission and Hippocampal-Dependent Memory

  2010influential citation
• Studying the Proliferation of Human Peripheral Blood T Lymphocytes in Serum-Free Medium

  2009cites this paper
• High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer

  2009cites this paper
• Novel Human Interleukin-15 Agonists

  2009cites this paper
• Identification of an interleukin-15 antagonist peptide that binds to IL-15R ααααα

  2009cites this paper
• NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.

  2008cites this paper
• Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

  2008cites this paper
• The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells

  2007cites this paper
• Role of proteins of the macroglobulin family in regulation of tumor growth

  2006cites this paper
• Role of proteins of the macroglobulin family in regulation of tumor growth

  2006cites this paper
• Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma

  2006cites this paper
• Decreased peritoneal concentrations of interleukin-15 in women with advanced stage endometriosis.

  2006cites this paper
• Renal cells express a functional interleukin-15 receptor.

  2005cites this paper
• High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth.

  2005cites this paper
• Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance.

  2005cites this paper
• Mechanisms of Superior Anti-Tumor Cytotoxic Response of Interleukin 15-Induced Lymphokine-Activated Killer Cells

  2005influential citation
• Failed Adoptive Immunotherapy with Tumor-Specific T Cells

  2004cites this paper
• Interleukin-2 Engineering for improved therapeutic effectiveness

  2004cites this paper
• CHAPTER 18 – Interleukin-15 and 21

  2003cites this paper
• Increased function and survival of IL‐15‐transduced human dendritic cells are mediated by up‐regulation of IL‐15Rα and Bcl‐2

  2002influential citation
• A novel design of targeted endocrine and cytokine therapy for breast cancer.

  2002cites this paper
• Systemic Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response Following Vaccination with Peptide-Pulsed Dendritic Cells

  2002cites this paper
• Peptide-Pulsed Dendritic Cells Response Following Vaccination with T Cell + the Antigen-Specific Primary CD8 Systemic Administration of IL-15 Augments

  2002cites this paper
• CellsAssociation with Syk in Human B Chain Signals Through α The IL-15 R

  2001cites this paper
• Serum levels of interleukin 15 in patients with rheumatic diseases.

  2001cites this paper
• The IL-15Rα Chain Signals Through Association with Syk in Human B Cells1

  2001cites this paper
• Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions.

  2001cites this paper
• The IL-15R alpha chain signals through association with Syk in human B cells.

  2001cites this paper
• Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications

  2001cites this paper
• Enhanced susceptibility to apoptosis in T cells recovering after autologous peripheral blood progenitor cell transplantation: reversal by interleukin-15.

  2000cites this paper